Jefferies Financial Group Inc. Makes New Investment in Inhibrx Biosciences, Inc. $INBX

Jefferies Financial Group Inc. bought a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,901 shares of the company’s stock, valued at approximately $703,000. Jefferies Financial Group Inc. owned 0.06% of Inhibrx Biosciences at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Strs Ohio acquired a new stake in Inhibrx Biosciences in the first quarter worth $27,000. Public Employees Retirement System of Ohio acquired a new stake in Inhibrx Biosciences in the third quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. increased its position in Inhibrx Biosciences by 26.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock worth $56,000 after buying an additional 147 shares during the period. BNP Paribas Financial Markets increased its position in Inhibrx Biosciences by 71.9% in the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after buying an additional 789 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Inhibrx Biosciences by 19.2% during the second quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock valued at $130,000 after purchasing an additional 1,469 shares during the period. 82.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on INBX shares. Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Zacks Research raised Inhibrx Biosciences to a “hold” rating in a report on Thursday, April 9th. Lifesci Capital raised Inhibrx Biosciences to a “strong-buy” rating in a report on Friday, April 24th. Finally, Stifel Nicolaus started coverage on Inhibrx Biosciences in a report on Wednesday, April 8th. They set a “buy” rating and a $150.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $150.00.

Inhibrx Biosciences Price Performance

Shares of INBX opened at $103.95 on Friday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -12.39 and a beta of 3.88. The company has a debt-to-equity ratio of 12.58, a quick ratio of 6.46 and a current ratio of 6.46. Inhibrx Biosciences, Inc. has a one year low of $12.72 and a one year high of $155.29. The stock’s fifty day moving average is $94.72 and its 200-day moving average is $84.06.

Inhibrx Biosciences (NASDAQ:INBX) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47). Equities analysts anticipate that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current year.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.